MRTF/SRF dependent transcriptional regulation of TAZ in breast cancer cells

Oncotarget

Volumn 7, Issue 12, 2016, Pages 13706-13716

  Liu, Chen Ying ^a,b   Chan, Siew Wee ^a   Guo, Fusheng ^a   Toloczko, Aleksandra ^a   Cui, Long ^a   Hong, Wanjin ^a  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Breast cancer; Heregulin 1 (HRG1); Hippo pathway; MRTF SRF; TAZ

Indexed keywords

MESSENGER RNA; MYOCARDIN RELATED TRANSCRIPTION FACTOR; NEU DIFFERENTIATION FACTOR; SERUM RESPONSE FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TAZ; UNCLASSIFIED DRUG; HEMOPROTEIN; HRG-1 PROTEIN, HUMAN; MKL1 PROTEIN, HUMAN; SRF PROTEIN, HUMAN; TAZ PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER CELL; CELL MIGRATION; CELL NUCLEUS; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; TRANSCRIPTION REGULATION; UPREGULATION; BREAST TUMOR; CELL MOTION; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR CELL CULTURE;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMEPROTEINS; HUMANS; SERUM RESPONSE FACTOR; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED;

EID: 84971655015     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7333     Document Type: Article

References (28)

1. Hansen CG, Moroishi T, Guan KL. YAP, TAZ: a nexus for Hippo signaling and beyond. Trends Cell Biol. 2015; 25:499-513.
2. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, Zheng P, Ye K, Chinnaiyan A, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes & development. 2007; 21:2747-2761.
3. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, Bicciato S, Elvassore N, Piccolo S. Role of YAP/TAZ in mechanotransduction. Nature. 2011; 474:179-183. doi: 10.18632/oncotarget.2997.
4. Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, WangLH, Zhao J, Yuan H, Tumaneng K, Li H, Fu XD, Mills GB, Guan KL. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012; 150:780-791.
5. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5:341-354.
6. Vellon L, Menendez JA, Lupu R. AlphaVbeta3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer. Oncogene. 2005; 24:3759-3773.
7. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. The Journal of biological chemistry. 1998; 273:28238-28246.
8. Tsai MS, Shamon-Taylor LA, Mehmi I, Tang CK, Lupu R. Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene. 2003; 22:761-768.
9. Haskins JW, Nguyen DX, Stern DF. Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration. Sci Signal. 2014; 7:ra116.
10. Nagashima T, Shimodaira H, Ide K, Nakakuki T, Tani Y, Takahashi K, Yumoto N, Hatakeyama M. Quantitative transcriptional control of ErbB receptor signaling undergoes graded to biphasic response for cell differentiation. The Journal of biological chemistry. 2007; 282:4045-4056.
11. Mi W, Lin Q, Childress C, Sudol M, Robishaw J, BerlotCH, Shabahang M, Yang W. Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration. Oncogene. 2015; 34:3095-3106.
12. Xiang L, Gilkes DM, Hu H, Takano N, Luo W, Lu H, BullenJW, Samanta D, Liang H, Semenza GL. Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype. Oncotarget. 2014; 5:12509-12527. doi: 10.18632/oncotarget.2997.
13. Paatero I, Jokilammi A, Heikkinen PT, Iljin K, KallioniemiOP, Jones FE, Jaakkola PM, Elenius K. Interaction with ErbB4 promotes hypoxia-inducible factor-1alpha signaling. J Biol Chem. 2012; 287:9659-9671.
14. Yang C, Liu Y, Lemmon MA, Kazanietz MG. Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4. Mol Cell Biol. 2006; 26:831-842.
15. Olson EN, Nordheim A. Linking actin dynamics and gene transcription to drive cellular motile functions. Nat Rev Mol Cell Biol. 2010; 11:353-365.
16. Qin B, Zhou M, Ge Y, Taing L, Liu T, Wang Q, WangS, Chen J, Shen L, Duan X, Hu S, Li W, Long H, et al. CistromeMap: a knowledgebase and web server for ChIP-Seq and DNase-Seq studies in mouse and human. Bioinformatics. 2012; 28:1411-1412.
17. Medjkane S, Perez-Sanchez C, Gaggioli C, Sahai E, Treisman R. Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis. Nat Cell Biol. 2009; 11:257-268.
18. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science signaling. 2013; 6:pl1.
19. Skibinski A, Breindel JL, Prat A, Galvan P, Smith E, Rolfs A, Gupta PB, Labaer J, Kuperwasser C. The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. Cell Rep. 2014; 6:1059-1072.
20. Ruan SQ, Wang ZH, Wang SW, Fu ZX, Xu KL, Li DB, Zhang SZ. Heregulin-beta1-induced GPR30 upregulation promotes the migration and invasion potential of SkBr3 breast cancer cells via ErbB2/ErbB3-MAPK/ERK pathway. Biochemical and biophysical research communications. 2012; 420:385-390.
21. Zhou X, Wang S, Wang Z, Feng X, Liu P, Lv XB, Li F, YuFX, Sun Y, Yuan H, Zhu H, Xiong Y, Lei QY, et al. Estrogen regulates Hippo signaling via GPER in breast cancer. The Journal of clinical investigation. 2015; 125:2123-2135.
22. Noguchi S, Saito A, Horie M, Mikami Y, Suzuki HI, Morishita Y, Ohshima M, Abiko Y, Mattsson JS, Konig H, Lohr M, Edlund K, Botling J, et al. An integrative analysis of the tumorigenic role of TAZ in human non-small cell lung cancer. Clin Cancer Res. 2014; 20:4660-4672.
23. Hossain Z, Ali SM, Ko HL, Xu J, Ng CP, Guo K, Qi Z, Ponniah S, Hong W, Hunziker W. Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1. Proc Natl Acad Sci U S A. 2007; 104:1631-1636.
24. Morin-Kensicki EM, Boone BN, Howell M, StonebrakerJR, Teed J, Alb JG, Magnuson TR, O'Neal W, Milgram SL. Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65. Mol Cell Biol. 2006; 26:77-87.
25. Diaz-Martin J, Lopez-Garcia MA, Romero-PerezL, Atienza-Amores MR, Pecero ML, Castilla MA, Biscuola M, Santon A, Palacios J. Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer. Endocr Relat Cancer. 2015; 22:443-454.
26. Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G, Benedetto AD, Todaro M, Stassi G, Sperati F, Amabile MI, Pilozzi E, Patrizii M, et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene. 2015; 34:681-690.
27. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A, Daidone MG, Dupont S, Basso G, et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011; 147:759-772.
28. Liu Y, Wang G, Yang Y, Mei Z, Liang Z, Cui A, Wu T, Liu CY, Cui L. Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial-mesenchymal transition and metastasis in a YAP-independent manner. Oncogene. 2015; doi: 10.1038/onc.2015.342. PMID: 26387538.